Top 5 Stocks with 200% Profit Growth in 2022

1. India Cements Ltd

India Cements Ltd is a leading cement manufacturing company based in Chennai. It was founded in 1946 by Shri S N N Sankaralinga Iyer and Sri T S Narayanaswami.

While keeping cement as its mainstay over the years, India Cements has ventured into related areas such as shipping, self-power and coal mining that have purposeful synergy with the core business. The company is also the sponsor of the IPL franchise “Chennai Super Kings”.

The company’s FY20 revenue was driven primarily by cement sales (95% of total revenue).

The company has 8 operating units in Tamil Nadu, Telangana, Andhra Pradesh and Rajasthan with a capacity of 15.55 million tonnes per annum. This is in contrast to 2 cement plants – one in Tamil Nadu and the other in Maharashtra.

Apart from the above plants, The Co also has 9 RMC plants.

Demand growth in the eastern region will be double-digit. There is a possibility that local plants in the region do not produce enough clinker and have to source it from states like Andhra Pradesh. At the same time, however, the contribution is much lower than in other regions, as demand rises sharply, there is a possibility that prices will rise in the east.

2. Bharat Petroleum Corporation Ltd

Bharat Petroleum Corporation is a public sector company engaged in oil refining and marketing of petroleum products.

A wholly owned subsidiary of Bharat PetroResources Ltd. it has holdings in 27 blocks, 15 of which are located in India and 12 overseas. It also has an equity stake in 2 Russian entities that have a licence for 4 production blocks in Russia.

BPRL blocks are in various stages of exploration, evaluation, pre-development and production. The total area held by BPRL and its subsidiaries is approximately 32,304 km2, of which approximately 57% is offshore.

The company owns its 7.8 MMTPA facility located in Madhya Pradesh through its subsidiary Bharat Oman Refineries Ltd.[11] The company acquired the remaining 36.6% stake in OQ S.A.O.C (non-controlling interest) for a consideration of 2,400 million in February 2021.

The Indian government gave its approval to privatize the company in November 2019. The privatization is expected to be completed in 2QFY22 and the government is expected to raise approximately ₹1,000 crore from the sale of its entire 53% stake in the company. company.

3. Jubilant Pharmova Ltd

Jubilant Pharmova Ltd is an integrated global pharmaceutical company with three business segments, namely Pharmaceuticals, Contract Research and Development Services and Patented New Medicines.

The pharmaceutical segment of the company is engaged in the manufacture, supply and distribution of radiopharmaceuticals, allergy products, CMOs, APIs, fixed dosage pharmaceuticals and branded Indian pharmaceuticals through 6 USFDA approved facilities in the US, Canada and India.

The company operates this business through its subsidiary Jubilant Therapeutics Inc. It is an innovative, patient-focused biopharmaceutical company developing breakthrough therapies in oncology and autoimmune disorders.

In February 2021, the company spun off its life sciences business into a new entity to unlock business value.

It also simplified the shareholder structure of the founder by merging the joint stock companies of the founder without changing the percentage of ownership and the number of shares held by the founders.

Company shareholders received 1 share of Jubilant Ingrevia Ltd for every 1 share held in Jubilant Life Sciences.

After the demerger, the company’s name changed from Jubilant Life Sciences Ltd to Jubilant Pharmova Ltd.

4. New India Assurance Company Ltd 

New India Assurance Company Ltd is India’s largest non-life insurance company. It is backed by the Government of India (GoI), which owns ~86% stake.

Founded by Sir Dorabji Tata in 1919, it was nationalized in 1973. After nationalization, it became one of the 4 subsidiaries of General Insurance Company of India (GIC), but gained autonomy after GIC became a reinsurance company in 1999.

The company is currently the market leader in health, motor, liability, fire and marine insurance.[5] It has ~14% market share in the general insurance industry in India.

In FY21, the company recorded gross written premiums of ~33,000 million crowns. Health and PA accounted for ~35% of GWP, followed by Fire (18%), Motor – Third Party (18%), Motor – Self Damage (13%), Sailor (3%) and Other (13%).

As of fiscal year 21, the company has investments of ~67,000 million crowns. Govt. securities and government-guaranteed bonds make up ~43% of total investments, followed by stocks (35%), infrastructure and housing (12%) and others (10%).

The company is strategically important to the government. India due to its dominant position in the market and being the flagship Indian general insurer in international markets, with a desk at the prestigious Lloyd’s syndicate in London. It can help the government. significantly improve insurance penetration in the country in the long term.

5. Sequent Scientific Ltd

Sequent Scientific is primarily engaged in the business of pharmaceuticals for animals.

In 2017, Sequent Scientific and Strides Shasun, two business entities belonging to the same promoter group, decided to separate their human API business and transferred the business to a new company, Solara Active Pharma Science Ltd. The split helped Sequent focus on its supply chain in animal health. India’s largest animal health company

Through its animal health subsidiary Alivira, Sequent Scientific is the largest animal health company from India and is among the top 20 animal health companies in the world. The company plans to build Alivira as the world’s leading pharmaceutical brand for animal health

Sequent has 4 global R&D centers and has invested more than $100 million in R&D by FY20. Due to its high focus on research and development, the company has more than 27+ commercial APIs and has filed 23 main drug files in the US and obtained 11 certificates of approval of suitability in the EU. It has a pipeline of 35 formulation products with more than 10 pending US filings targeted in the next two to three years.

In the last 5 years, the company has made eight acquisitions worth INR 4 billion. As the company has a strong track record of multi-company acquisitions, management intends to add meaningful leverage to support further inorganic growth.